What NFX Is Thinking

Synthesized from 15 recent items.

AI & agents

Biotech / life sciences

  • Seed-stage biotech can now reach human trials for under $10M — same infra cost collapse as cloud. In Vitro, In Vivo, In China
  • China overtook the US in clinical trial volume in 2025; 30–40% lower costs, growing regulatory friction risk. In Vitro, In Vivo, In China
  • Capstan: dosed in China seed-stage, acquired by AbbVie for $2.1B mid-Phase I. The playbook works. In Vitro, In Vivo, In China
  • Centivax in Phase 1 for universal flu vaccine; platform extends to pan-herpes Alzheimer’s, malaria, universal antivenom. Centivax Universal Flu Vaccine
  • Women’s health is the biggest undervalued market in healthcare; platform play targets $30B by 2030. Cyclana Bio
  • Longevity crossed from fringe to mainstream in 2025. NFX frames aging itself as a startup-sized problem. The Founder’s Guide to JPM

Founders & company building

Space infrastructure


Last updated: 2026-04-15 15:48 UTC


Type Markdown
Added Apr 15, 2026
Modified Apr 15, 2026